Michael Liptay to Combined Modality Therapy
This is a "connection" page, showing publications Michael Liptay has written about Combined Modality Therapy.
Connection Strength
0.303
-
Multimodality treatment of pleural mesothelioma. Surg Oncol Clin N Am. 2013 Apr; 22(2):345-55.
Score: 0.105
-
Pneumonectomy after chemoradiation therapy for non-small cell lung cancer: does "side" really matter? Ann Thorac Surg. 2009 Sep; 88(3):937-43; discussion 944.
Score: 0.083
-
Comparative effectiveness of neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery for patients with stage IIIA non-small cell lung cancer. Lung Cancer. 2015 Jun; 88(3):267-74.
Score: 0.031
-
Esophageal carcinoma advances in treatment results for locally advanced disease: review. Ann Oncol. 2012 May; 23(5):1095-1103.
Score: 0.024
-
Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients. J Thorac Oncol. 2011 Jun; 6(6):1079-86.
Score: 0.023
-
The incidence of perioperative anastomotic complications after sleeve lobectomy is not increased after neoadjuvant chemoradiotherapy. Ann Thorac Surg. 2009 Sep; 88(3):945-50; discussion 950-1.
Score: 0.021
-
Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Ann Surg. 1996 Sep; 224(3):288-94; discussion 294-6.
Score: 0.008
-
An historical perspective of multi-modality treatment for resectable non-small cell lung cancer. Lung Cancer. 1995 Jun; 12 Suppl 2:S17-32.
Score: 0.008